Literature DB >> 10619437

Mechanisms of brain-mediated systemic anti-inflammatory syndrome causing immunodepression.

C Woiciechowsky1, B Schöning, W R Lanksch, H D Volk, W D Döcke.   

Abstract

Overwhelming inflammatory immune response can result in systemic inflammation and septic shock. To prevent excessive and deleterious action of proinflammatory cytokines after they have produced their initial beneficial effects, the immune system can release several anti-inflammatory mediators, including interleukin-10, interleukin-1 receptor antagonist, and soluble tumor necrosis factor receptors, thus initiating a compensatory anti-inflammatory response syndrome. However, in vivo the delicate balance between pro- and anti-inflammatory responses is additionally controlled by the central nervous system. Therefore, proinflammatory cytokines stimulate the hypothalamic-pituitary-adrenal axis and enhance sympathetic nerve system activity. The mediators of these neuroimmune pathways can again suppress immune cell functions to control systemic inflammation. The question is, however, what happens if the immunoinhibitory CNS pathways are activated without systemic inflammation? This can result from production of cytokines in the brain following infection, injury, or ischemia or in response to various stressors (e.g., life events, depression, anxiety) or directly from brainstem irritation. The answer is that this may generate a brain-mediated immunodepression. Many animal and clinical studies have demonstrated a stress and brain cytokine mediated decrease in the cellular immune response at the lymphocyte level. More recently, the importance of monocytes in systemic immunocapacity has been shown. Monocytic inactivation with decreased capability of antigen presentation and depressed secretion of proinflammatory cytokines increases the risk of infectious complications. Interestingly, cytokines in the brain and other stressors can also generate systemic immunodepression at the monocyte level. In this scenario the catecholamine-induced release of the potent anti-inflammatory cytokine interleukin-10 is a newly discovered mechanism of the brain-mediated monocyte deactivation in addition to the "well known" immunosuppressive action of glucocorticoids. Furthermore, other neuropeptides such as alpha-melanocyte-stimulating hormone and beta-endorphin which can be released in stressful situations have also inhibitory effects on immune cells. Thus mediators of the CNS are implicated in the regulation of immune functions and may play a role in both conditioning the host's response to endogenous or exogenous stimuli and generating a "brain-mediated" immunodepression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10619437     DOI: 10.1007/s001099900051

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  34 in total

Review 1.  The immunology of acute stroke.

Authors:  Ángel Chamorro; Andreas Meisel; Anna M Planas; Xabier Urra; Diederik van de Beek; Roland Veltkamp
Journal:  Nat Rev Neurol       Date:  2012-06-05       Impact factor: 42.937

2.  Tolerogenic effect of fiber tract injury: reduced EAE severity following entorhinal cortex lesion.

Authors:  Leman Mutlu; Christine Brandt; Erik Kwidzinski; Birgit Sawitzki; Ulrike Gimsa; Jacqueline Mahlo; Orhan Aktas; Robert Nitsch; Marloes van Zwam; Jon D Laman; Ingo Bechmann
Journal:  Exp Brain Res       Date:  2006-11-08       Impact factor: 1.972

Review 3.  Molecular dialogs between the ischemic brain and the peripheral immune system: dualistic roles in injury and repair.

Authors:  Chengrui An; Yejie Shi; Peiying Li; Xiaoming Hu; Yu Gan; Ruth A Stetler; Rehana K Leak; Yanqin Gao; Bao-Liang Sun; Ping Zheng; Jun Chen
Journal:  Prog Neurobiol       Date:  2013-12-26       Impact factor: 11.685

Review 4.  Immunoparalysis and adverse outcomes from critical illness.

Authors:  W Joshua Frazier; Mark W Hall
Journal:  Pediatr Clin North Am       Date:  2008-06       Impact factor: 3.278

5.  Blocking Sympathetic Nervous System Reverses Partially Stroke-Induced Immunosuppression but does not Aggravate Functional Outcome After Experimental Stroke in Rats.

Authors:  Qi-Wen Deng; Heng Yang; Fu-Ling Yan; Huan Wang; Fang-Lan Xing; Lei Zuo; Han-Qing Zhang
Journal:  Neurochem Res       Date:  2016-04-08       Impact factor: 3.996

6.  Corticotropin releasing factor-1 receptor antagonism alters the biochemical, but not behavioral effects of repeated interleukin-1β administration.

Authors:  Clare J Wilhelm; Aaron Murphy-Crews; Daniel J Menasco; Marilyn S Huckans; Jennifer M Loftis
Journal:  Neuropharmacology       Date:  2011-08-04       Impact factor: 5.250

7.  PATHOLOGICAL ASPECTS OF THE ANTI-INFLAMMATORY/IMMUNE SUPPRESSIVE RESPONSE IN SEPSIS AND SHOCK.

Authors:  Alfred Ayala; Yanli Ding; Rebecca J Rhee; Lesley A Doughty; Patrician S Grutkoski; Chun-Shiang Chung
Journal:  Rec Res Dev Immunol       Date:  2003-01-12

8.  Blocking stroke-induced immunodeficiency increases CNS antigen-specific autoreactivity but does not worsen functional outcome after experimental stroke.

Authors:  Christine Römer; Odilo Engel; Katarzyna Winek; Sonja Hochmeister; Tian Zhang; Georg Royl; Juliane Klehmet; Ulrich Dirnagl; Christian Meisel; Andreas Meisel
Journal:  J Neurosci       Date:  2015-05-20       Impact factor: 6.167

9.  Diurnal cortisol rhythms among Latino immigrants in Oregon, USA.

Authors:  Erica C Squires; Heather H McClure; Charles R Martinez; J Mark Eddy; Roberto A Jiménez; Laura E Isiordia; J Josh Snodgrass
Journal:  J Physiol Anthropol       Date:  2012-06-25       Impact factor: 2.867

10.  Metastatic-promoting effects of LPS: sexual dimorphism and mediation by catecholamines and prostaglandins.

Authors:  Ranit Naor; Vered Domankevich; Shaily Shemer; Luba Sominsky; Ella Rosenne; Ben Levi; Shamgar Ben-Eliyahu
Journal:  Brain Behav Immun       Date:  2008-10-08       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.